However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 million (around $16 million ...

PI Industries Ltd., incorporated in the year 1946, is a Large Cap company (having a market cap of Rs 54,913.61 Crore) operating in Pesticides/Agro Chemicals sector. PI Industries Ltd. key ...

$ 84.38-0.07-0.08% ...

After hours: 7:59:50 p.m. EST Loading Chart for NVO ...